0000921114 false 0000921114 2021-08-12 2021-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): August 12, 2021



(Exact name of Registrant as specified in its charter)


Washington 001-37544 91-1549568
(State or other jurisdiction of incorporation or
(Commission File Number) (IRS Employer Identification No.)


4503 Glencoe Avenue

Marina del Rey, California



(Address of principal executive offices) (Zip Code)


(310) 655-2928

(Registrant’s Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which
Common Stock, par value $0.01 per share   ARMP   NYSE American







Item 2.02Results of Operations and Financial Condition.


On August 12, 2021, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2021, in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.


The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached exhibit shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


99.1   Press Release.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 12, 2021 Armata Pharmaceuticals, Inc.
  By: /s/ Steve R. Martin
  Name:  Steve R. Martin
  Title: Chief Financial Officer



EX-99.1 2 tm2125001d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1




Armata Pharmaceuticals Announces Second Quarter Results and Provides

General Corporate Update


Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa


Announced that Todd R. Patrick, CEO, has retired from the Company. Brian Varnum, PhD, former President and Chief Development Officer, has been appointed the Company’s new CEO


MARINA DEL REY, Calif., August 12, 2021 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the second quarter of 2021 and provided a corporate update.


Second Quarter 2021 and Recent Developments:


·Announced that Todd R. Patrick, Chief Executive Officer, has retired from the company. Armata’s Board of Directors has appointed Brian Varnum, PhD, the company’s former President and Chief Development Officer, to succeed Mr. Patrick. Mr. Patrick will retain his seat on Armata’s Board and has agreed to serve as an advisor to the company at least through 2022.


·Continued to advance the SWARM-P.a. trial and received a milestone payment of $750,000 pursuant to the Company’s previously announced Therapeutics Development Award from the Cystic Fibrosis Foundation. The award, up to $5 million, is intended to partially fund Armata’s Phase 1b/2a clinical trial of its lead clinical candidate, AP-PA02, as a treatment for chronic Pseudomonas aeruginosa airway infections in people with cystic fibrosis.


·Progressed IND-enabling activities in preparation for a Phase 1b/2 clinical trial evaluating AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia.


“We continue to make good progress advancing our lead phage product for chronic Pseudomonas airway infections in people with cystic fibrosis. We are very appreciative of the continued support from the Cystic Fibrosis Foundation and the Therapeutics Development Network as we have navigated the challenges of conducting a clinical trial in the respiratory space during COVID-19,” stated Brian Varnum, PhD, Chief Executive Officer of Armata. “In addition, our pipeline programs are advancing. With the support of the U.S. Department of Defense, our phage product for Staphylococcus aureus bacteremia, AP-SA02, is progressing towards an IND filing. We are also leveraging our lead products and our proprietary phage library to identify the next clinical indication to prioritize.”


Anticipated 2021 and 2022 Milestones:


·Complete the SWARM-P.a. Phase 1b/2a clinical trial


·Initiate a Phase 1b/2 clinical trial evaluating AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia


·Initiate at least one additional clinical trial in a new indication






Second Quarter 2021 Financial Results


Grant Revenue. The Company recognized grant revenue of $1.2 million for the three months ended June 30, 2021, which represents Medical Technology Enterprise Consortium (MTEC)’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $15.0 million in grant funding from MTEC over a three-year period administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized $31,000 of revenue in the comparable period in 2020.


Research and Development. Research and development expenses for the three months ended June 30, 2021 were approximately $5.2 million as compared to $2.6 million for the comparable period in 2020. The increase was primarily related to the increase in clinical trial and personnel related expenses.


General and Administrative. General and administrative expenses for the three months ended June 30, 2021 were $2.1 million as compared to $2.0 million for the comparable period in 2020.


Loss from Operations. Loss from operations for the three months ended June 30, 2021 was $(6.2) million as compared to a loss from operations of $(4.6) million for the comparable period in 2020.


Cash and Equivalents. As of June 30, 2021, Armata held approximately $17.5 million of unrestricted cash and cash equivalents, as compared to $9.7 million as of December 31, 2020.


As of August 12, 2021, there were approximately 24.9 million shares of common stock outstanding.


About Armata Pharmaceuticals, Inc.


Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.


Forward Looking Statements


This communication contains "forward-looking" statements, including, without limitation, statements related to Armata's bacteriophage development programs, Armata's ability to meet expected milestones, Armata's ability to be a leader in the development of phage-based therapeutics, and statements related to the timing and results of clinical trials, including the anticipated results of clinical trials of AP-PA02 and AP-SA02, and Armata's ability to develop new products based on bacteriophages and synthetic phages. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of Armata's lead clinical candidates, AP-PA02 and AP-SA02, to be more effective than previous candidates; Armata's ability to expedite development of AP-PA02; Armata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process; Armata's ability to develop products based on bacteriophages and synthetic phages to kill bacterial pathogens; the Company's expected market opportunity for its products; Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed; and any delays or adverse events within, or outside of, Armata's control, caused by the ongoing outbreak of COVID-19. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 18, 2021, and in its subsequent filings with the SEC.






Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


Media Contacts:


At Armata:

Steve Martin

Armata Pharmaceuticals, Inc.




Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC








Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets


   June 30, 2021   December 31, 2020 
Cash and cash equivalents  $17,536,000   $9,649,000 
Award receivable   1,168,000    561,000 
Prepaids and other current assets   1,005,000    636,000 
Total current assets   19,709,000    10,846,000 
Property and equipment, net   12,739,000    12,837,000 
Other long term assets   2,087,000    2,087,000 
Intangible assets, net   13,746,000    13,746,000 
Total assets  $48,281,000   $39,516,000 
Liabilities and stockholders’ equity          
Total current liabilities  $5,903,000   $6,705,000 
Long term liabilities   10,682,000    10,877,000 
Deferred tax liability   3,077,000    3,077,000 
Total liabilities   19,662,000    20,659,000 
Stockholders’ equity   28,619,000    18,857,000 
Total liabilities and stockholders’ equity  $48,281,000   $39,516,000 






Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations


   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
Revenue  $1,168,000   $31,000    2,234,000    31,000 
Operating expenses:                    
Research and development   5,225,000    2,648,000   $9,575,000   $5,398,000 
General and administrative   2,139,000    1,973,000    4,290,000    4,144,000 
Total operating expenses   7,364,000    4,621,000    13,865,000    9,542,000 
Loss from operations   (6,196,000)   (4,590,000)   (11,631,000)   (9,511,000)
Other income (expense):                    
Other income (expense), net   2,000    (120,000)   (58,000)   (277,000)
Total other income (expense), net   2,000    (120,000)  $(58,000)   (277,000)
Loss before income taxes and Net Loss  $(6,194,000)  $(4,710,000)   (11,689,000)  $(9,788,000)
Net loss per share, basic and diluted  $(0.25)  $(0.26)   (0.52)  $(0.68)
Weighted average shares outstanding, basic and diluted   24,762,818    18,347,051    22,622,477    14,399,399 






Armata Pharmaceuticals, Inc.

Condensed Consolidated Statement of Cash Flows


   Six Months Ended June 30, 
   2021   2020 
Operating activities:          
Net loss  $(11,689,000)  $(9,788,000)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Change in fair value of derivative liabilities          
Stock-based compensation   1,749,000    1,950,000 
Depreciation   578,000    575,000 
Non-cash interest expense   62,000    300,000 
Payment of accreted interest for deferred consideration for asset acquisition   (586,000)   - 
Changes in operating assets and liabilities, net   (127,000)   (1,125,000)
Net cash used in operating activities   (10,013,000)   (8,088,000)
Investing activities:          
Purchases of property and equipment, net   (494,000)   (377,000)
Net cash used in investing activities   (494,000)   (377,000)
Financing activities:          
Principal payment of deferred consideration for asset acquisition   (1,414,000)   (1,000,000)
Proceeds from Paycheck Protection Program Loan   -    718,000 
Proceeds from warrant and option exercises   445,000    81,000 
Procees from private placement financing, net   19,363,000    22,919,000 
Net cash provided by (used in) financing activities   18,394,000    22,718,000 
Net increase (decrease) in cash and cash equivalents   7,887,000    14,253,000 
Cash, cash equivalents and restricted cash, beginning of period   10,849,000    6,733,000 
Cash, cash equivalents and restricted cash, end of period  $18,736,000   $20,986,000 
Reconciliation of Cash and cash equivalents:   Six Months Ended June 30, 
    2021    2020 
Cash and cash equivalents  $17,536,000   $19,786,000 
Restricted cash   1,200,000    1,200,000 
Cash, cash equivalents and restricted cash  $18,736,000   $20,986,000 



EX-101.SCH 3 armp-20210812.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 armp-20210812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 armp-20210812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2125001d1_ex99-1img001.jpg GRAPHIC begin 644 tm2125001d1_ex99-1img001.jpg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end XML 7 tm2125001d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000921114 2021-08-12 2021-08-12 iso4217:USD shares iso4217:USD shares 0000921114 false 8-K 2021-08-12 ARMATA PHARMACEUTICALS, INC. WA 001-37544 91-1549568 4503 Glencoe Avenue Marina del Rey CA 90292 310 655-2928 false false false false false Common Stock, par value $0.01 per share ARMP NYSEAMER XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Aug. 12, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2021
Entity File Number 001-37544
Entity Central Index Key 0000921114
Entity Tax Identification Number 91-1549568
Entity Incorporation, State or Country Code WA
Entity Address, Address Line One 4503 Glencoe Avenue
Entity Address, City or Town Marina del Rey
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90292
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://armatapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2125001d1_8k.htm armp-20210812.xsd armp-20210812_lab.xml armp-20210812_pre.xml tm2125001d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2125001d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2125001d1_8k.htm" ] }, "labelLink": { "local": [ "armp-20210812_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "armp-20210812_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "armp-20210812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "armp", "nsuri": "http://armatapharma.com/20210812", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2125001d1_8k.htm", "contextRef": "From2021-08-12to2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://armatapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2125001d1_8k.htm", "contextRef": "From2021-08-12to2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-104359-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-104359-xbrl.zip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�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end